Is PepGen Inc. (PEPG) a Buy, Sell, or Hold?
NASDAQ : PEPG
PepGen Inc.
$2.85 USD
$0.44 (18.26%)
- Volume
- 3.21M
- Average Volume
- 842.17K
- Market Capitalization
- $197.13M
- P/E Ratio
- -1.90
- Dividend Yield
- 0.00%
- Price Target
- $5.50
- Year High
- $7.80
- Year Low
- $1.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.36
Company Overview
NASDAQ
James McArthur
Biotechnology
Healthcare
PEPG
56
US
USD
Liquidity Metrics
0.13
13.36
13.36
2.53
0.00
Sales & Valuation
-$
0.00
1.65
-2.84
-1.00
Profitability
-$2.12
-$89.66M
0.00%
0.00%
-51.01%
-50.88%
P/E Metrics
-1.90
-0.03
-0.03
Analyst Price Target & Rating
$5.50
$7.00
$4.00
2/5
6 Analysts
-48.18%
Financial Health Scores
0.70
2/9
$111.32M
$141.4M
$21.86M
-$73.9M
Key Metrics (TTM)
$190.46M
0.00
-2.81
13.36
-51.01%
-56.21%
-36.48%
-35.24%
-233 days
Company Executives
| Name | Title |
|---|---|
| James G. McArthur | President, Chief Executive Officer, Treasurer, Secretary & Director |
| Hayley Parker | Senior Vice President of Global Regulatory Affairs & Quality |
| Kasra Kasraian | Chief Technology Officer |
| Joseph D. Vittiglio | Chief Business & Legal Officer and Secretary |
| Paul D. Streck | Executive Vice President and Head of Research & Development |
| Emiko Bryant | Senior Vice President of HR & Administration |
| Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC |
| Gregory Song | Executive Director & Head of Biometrics |
| Pallavi Lonkar | Vice President & Head of Preclinical |
| Noel Donnelly | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About PepGen Inc. (NASDAQ:PEPG) Stock
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts. ...
2026-08-06 08:00:00
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-06 08:00:00
[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of tran
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-06 07:32:00
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.
2026-08-06 07:30:00
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.
2026-05-21 07:00:00
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that data from its PGN-EDODM1 program will be presented in a poster and late-breaking oral presentation at the 15th International Myotonic Dystrophy Consortium (IDMC-15) being held May 26-30, 2026, in Saguenay, Quebec, Canada. The late-b.
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-05-20 10:35:25
PepGen (PEPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
2026-05-13 13:01:21
PepGen (PEPG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-12 16:05:00
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2026, and recent corporate highlights. "We made encouraging progress during the first quarter of 2026 in our FREEDOM2-DM1 trial. The 5 mg/kg cohort — the in.
Frequently Asked Questions
-
What is the current PepGen Inc. (PEPG) stock price?
-
PepGen Inc.(NASDAQ:PEPG) stock price is $2.85 in the last trading session. During the trading session, PEPG stock reached the peak price of $7.8 while $1.01 was the lowest point it dropped to. The percentage change in PEPG stock occurred in the recent session was 18.26% while the dollar amount for the price change in PEPG stock was $0.44.
-
PEPG's industry and sector of operation?
-
The NASDAQ listed PEPG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of PEPG?
-
James G. McArthur | President, Chief Executive Officer, Treasurer, Secretary & Director
Hayley Parker | Senior Vice President of Global Regulatory Affairs & Quality
Kasra Kasraian | Chief Technology Officer
Joseph D. Vittiglio | Chief Business & Legal Officer and Secretary
Paul D. Streck | Executive Vice President and Head of Research & Development -
How many employees does PEPG have?
-
Number of PEPG employees currently stands at 56. PEPG operates from 321 Harrison Avenue, Boston, MA 02118, US.
-
Link for PEPG official website?
-
Official Website of PEPG is: https://www.pepgen.com
-
How do I contact PEPG?
-
PEPG could be contacted at phone #781-797-0979 and can also be accessed through its website. PEPG operates from 321 Harrison Avenue, Boston, MA 02118, US.
-
How many shares of PEPG are traded daily?
-
The average number of PEPG shares traded daily for last 3 months was 842.17K.
-
What is the market cap of PEPG currently?
-
The market value of PEPG currently stands at $197.13M with its latest stock price at $2.85